The article discusses a randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer. It references a study by Natasha B. Leighl et al, published in a 2010 issue of the "Journal of the National Cancer Institute." The researchers recorded an incremental cost-effectiveness ratio for erlotinib of 94,638 U.S. dollars per life-year gained. Other research findings are presented.